In a patient recently hospitalized for decompensated congestive heart failure, should I continue all heart‑failure medications rather than stop them because stopping could worsen fluid overload?

Continuation of Heart Failure Medications During Acute Decompensation

You were absolutely correct to continue the medications—stopping guideline-directed medical therapy (GDMT) during acute decompensated heart failure typically worsens outcomes, and the fear of fluid overload from continuing these drugs is largely unfounded. 1

Why Continuing GDMT Is Critical

Beta-blockers, ACE-inhibitors/ARBs/ARNi, and mineralocorticoid receptor antagonists should be maintained throughout acute decompensation unless the patient develops hemodynamic instability (cardiogenic shock, symptomatic hypotension despite optimization, or requires beta-agonist inotropes). 2, 1 The 2022 AHA/ACC/HFSA guidelines explicitly state that discontinuation of beta-blockers during hospitalization is associated with higher mortality compared to continuation. 2

The Evidence Against Stopping

• Observational data from OPTIMIZE-HF demonstrated that patients who had beta-blockers discontinued during hospitalization had significantly higher mortality risk than those who continued them. 2
• Discharge use of carvedilol specifically was associated with reduced 60- to 90-day mortality and composite risk of death or rehospitalization. 2
• Available data, mostly observational, shows that continuation or initiation of renin-angiotensin-aldosterone system inhibitors appears efficacious, safe, and well tolerated in the majority of acute heart failure patients during hospitalization. 3

Addressing the Fluid Overload Concern

The medications you continued do not cause fluid overload—they treat the underlying pathophysiology of heart failure. Here's why your concern about fluid accumulation is misplaced:

• Loop diuretics are the primary tool for managing congestion and fluid overload, not GDMT discontinuation. 2, 1 Patients with significant fluid overload should be promptly treated with intravenous loop diuretics at doses equal to or greater than their home oral dose. 2, 1
• Worsening renal function portends poor prognosis only if associated with persistent congestion—clinicians should not de-escalate diuretic therapy routinely for worsening renal function alone. 3
• Do not discontinue GDMT for mild renal function decline or asymptomatic blood-pressure reductions, as premature withdrawal worsens long-term outcomes. 1

When to Temporarily Reduce or Hold GDMT

The only scenarios requiring temporary adjustment are:

ACE-Inhibitors/ARBs/MRAs

• Continue standard dosing when serum creatinine is <200 µmol/L (<2.26 mg/dL), with more frequent monitoring of potassium and creatinine. 1
• If creatinine rises >30% from baseline in a non-oliguric patient, reduce doses of diuretics, ACE-I/ARB, and spironolactone until renal function stabilizes—but do not stop them entirely. 1
• In oliguric but hemodynamically stable patients, review daily but continue unless creatinine exceeds 250 µmol/L (2.83 mg/dL) or has increased >50% from baseline. 1

Beta-Blockers

• Maintain beta-blockers unless the patient is in cardiogenic shock, has symptomatic hypotension despite optimization of other therapies, or requires a beta-agonist inotropic agent. 1
• Use beta-blockers cautiously in hypotensive patients, but do not routinely discontinue. 1

The Real Problem: Underuse of GDMT

The actual clinical problem is the opposite of what you feared—most patients are discharged on inadequate or no GDMT:

• Based on claims data, roughly 42% of patients are not prescribed any GDMT within 30 days post-hospitalization, and 45% are prescribed either no oral GDMT or monotherapy within 1 year post-hospitalization. 2
• Very few patients with HFrEF receive target doses of oral GDMT, and most have no changes made to GDMT over 12 months despite being discharged on suboptimal doses. 2
• It cannot be assumed that oral GDMT will be initiated or optimized after hospitalization—it must be done during the admission. 2

Practical Management Algorithm

1. Continue all GDMT (beta-blockers, ACE-I/ARB/ARNI, MRAs, SGLT2 inhibitors) at admission unless contraindicated. 1
2. Treat congestion aggressively with IV loop diuretics at doses ≥ home oral dose. 2, 1
3. Monitor daily: symptoms, urine output, weight, vital signs, creatinine, potassium. 1
4. If creatinine rises <30% and patient remains non-oliguric, continue GDMT and escalate diuretics. 1
5. Only reduce GDMT doses if creatinine rises >30% in non-oliguric patients or >50% in any patient. 1
6. Never stop beta-blockers unless cardiogenic shock, symptomatic hypotension, or need for dobutamine/milrinone. 1
7. Before discharge, ensure GDMT is optimized—this is a Class 1 recommendation. 2

Common Pitfalls to Avoid

• Do not discontinue GDMT prematurely for minor blood-pressure or renal-function changes—this is explicitly discouraged in guidelines. 1
• Do not assume diuretics alone will manage heart failure—they treat symptoms (congestion) but GDMT treats the disease and prevents mortality. 2
• Do not delay GDMT optimization until after discharge—most patients never receive it if not started in hospital. 2

Your instinct to continue medications was evidence-based and correct. The key is aggressive diuresis to manage congestion while maintaining the disease-modifying therapies that prevent death and rehospitalization. 2, 1